These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 24782851)

  • 21. Influenza virus partially counteracts restriction imposed by tetherin/BST-2.
    Mangeat B; Cavagliotti L; Lehmann M; Gers-Huber G; Kaur I; Thomas Y; Kaiser L; Piguet V
    J Biol Chem; 2012 Jun; 287(26):22015-29. PubMed ID: 22493439
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Vpu serine 52 dependent counteraction of tetherin is required for HIV-1 replication in macrophages, but not in ex vivo human lymphoid tissue.
    Schindler M; Rajan D; Banning C; Wimmer P; Koppensteiner H; Iwanski A; Specht A; Sauter D; Dobner T; Kirchhoff F
    Retrovirology; 2010 Jan; 7():1. PubMed ID: 20078884
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cell-cell spread of human immunodeficiency virus type 1 overcomes tetherin/BST-2-mediated restriction in T cells.
    Jolly C; Booth NJ; Neil SJ
    J Virol; 2010 Dec; 84(23):12185-99. PubMed ID: 20861257
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anti-tetherin activities in Vpu-expressing primate lentiviruses.
    Yang SJ; Lopez LA; Hauser H; Exline CM; Haworth KG; Cannon PM
    Retrovirology; 2010 Feb; 7():13. PubMed ID: 20167081
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A cytoplasmic tail determinant in HIV-1 Vpu mediates targeting of tetherin for endosomal degradation and counteracts interferon-induced restriction.
    Kueck T; Neil SJ
    PLoS Pathog; 2012; 8(3):e1002609. PubMed ID: 22479182
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A rare missense variant abrogates the signaling activity of tetherin/BST-2 without affecting its effect on virus release.
    Sauter D; Hotter D; Engelhart S; Giehler F; Kieser A; Kubisch C; Kirchhoff F
    Retrovirology; 2013 Aug; 10():85. PubMed ID: 23937976
    [TBL] [Abstract][Full Text] [Related]  

  • 27. β-TrCP is dispensable for Vpu's ability to overcome the CD317/Tetherin-imposed restriction to HIV-1 release.
    Tervo HM; Homann S; Ambiel I; Fritz JV; Fackler OT; Keppler OT
    Retrovirology; 2011 Feb; 8():9. PubMed ID: 21310048
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tetherin antagonism by primate lentiviral nef proteins.
    Sauter D; Kirchhoff F
    Curr HIV Res; 2011 Oct; 9(7):514-23. PubMed ID: 22103835
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Restriction of Retroviral Replication by Tetherin/BST-2.
    Hammonds J; Wang JJ; Spearman P
    Mol Biol Int; 2012; 2012():424768. PubMed ID: 22811908
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The ESCRT-0 component HRS is required for HIV-1 Vpu-mediated BST-2/tetherin down-regulation.
    Janvier K; Pelchen-Matthews A; Renaud JB; Caillet M; Marsh M; Berlioz-Torrent C
    PLoS Pathog; 2011 Feb; 7(2):e1001265. PubMed ID: 21304933
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Structural Basis for the Antiviral Activity of BST-2/Tetherin and Its Viral Antagonism.
    Arias JF; Iwabu Y; Tokunaga K
    Front Microbiol; 2011; 2():250. PubMed ID: 22180752
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tetherin and its viral antagonists.
    Kuhl BD; Cheng V; Wainberg MA; Liang C
    J Neuroimmune Pharmacol; 2011 Jun; 6(2):188-201. PubMed ID: 21222046
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification of alternatively translated Tetherin isoforms with differing antiviral and signaling activities.
    Cocka LJ; Bates P
    PLoS Pathog; 2012 Sep; 8(9):e1002931. PubMed ID: 23028328
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vpu directs the degradation of the human immunodeficiency virus restriction factor BST-2/Tetherin via a {beta}TrCP-dependent mechanism.
    Douglas JL; Viswanathan K; McCarroll MN; Gustin JK; Früh K; Moses AV
    J Virol; 2009 Aug; 83(16):7931-47. PubMed ID: 19515779
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Filamin A Is Involved in HIV-1 Vpu-mediated Evasion of Host Restriction by Modulating Tetherin Expression.
    Dotson D; Woodruff EA; Villalta F; Dong X
    J Biol Chem; 2016 Feb; 291(8):4236-46. PubMed ID: 26742839
    [TBL] [Abstract][Full Text] [Related]  

  • 36. BST-2/tetherin: viral tether, viral sensor or both?
    Gustin JK; Douglas JL
    Future Virol; 2013 Nov; 8(11):. PubMed ID: 24396393
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vpu of a Simian Immunodeficiency Virus Isolated from Greater Spot-Nosed Monkey Antagonizes Human BST-2 via Two AxxxxxxxW Motifs.
    Yao W; Yoshida T; Hashimoto S; Takeuchi H; Strebel K; Yamaoka S
    J Virol; 2020 Jan; 94(2):. PubMed ID: 31666374
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tetherin/BST-2 antagonism by Nef depends on a direct physical interaction between Nef and tetherin, and on clathrin-mediated endocytosis.
    Serra-Moreno R; Zimmermann K; Stern LJ; Evans DT
    PLoS Pathog; 2013; 9(7):e1003487. PubMed ID: 23853598
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adaptation of human and simian immunodeficiency viruses for resistance to tetherin/BST-2.
    Serra-Moreno R; Evans DT
    Curr HIV Res; 2012 Jun; 10(4):277-82. PubMed ID: 22524175
    [TBL] [Abstract][Full Text] [Related]  

  • 40. HIV-1 Vpu and HIV-2 Env counteract BST-2/tetherin by sequestration in a perinuclear compartment.
    Hauser H; Lopez LA; Yang SJ; Oldenburg JE; Exline CM; Guatelli JC; Cannon PM
    Retrovirology; 2010 Jun; 7():51. PubMed ID: 20529266
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.